Nifty
Sensex
:
:
24586.70
80664.86
84.55 (0.35%)
145.52 (0.18%)

Pharmaceuticals & Drugs - Domestic

Rating :
62/99

BSE: 539523 | NSE: ALKEM

5063.55
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  4990.90
  •  5085.00
  •  4990.60
  •  4981.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  166745
  •  8427.44
  •  5578.80
  •  3447.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 62,086.52
  • 34.57
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 61,721.14
  • 0.77%
  • 6.02

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 56.38%
  • 0.11%
  • 16.15%
  • FII
  • DII
  • Others
  • 8.69%
  • 17.57%
  • 1.10%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.01
  • 9.53
  • 9.37

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.66
  • 7.62
  • -3.69

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.50
  • 5.29
  • -14.69

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 28.75
  • 27.55
  • 33.39

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.81
  • 4.81
  • 4.91

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.03
  • 19.89
  • 21.01

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Net Sales
2,935.82
2,902.60
1.14%
3,323.87
3,040.91
9.31%
3,440.17
3,079.37
11.72%
2,967.72
2,576.38
15.19%
Expenses
2,533.84
2,549.35
-0.61%
2,616.28
2,441.86
7.14%
2,693.44
2,625.46
2.59%
2,578.53
2,373.14
8.65%
EBITDA
401.98
353.25
13.79%
707.59
599.05
18.12%
746.73
453.91
64.51%
389.19
203.24
91.49%
EBIDTM
13.69%
12.17%
21.29%
19.70%
21.71%
-4.88%
13.11%
7.89%
Other Income
88.17
68.67
28.40%
93.64
45.33
106.57%
63.19
50.67
24.71%
65.84
51.41
28.07%
Interest
26.86
28.96
-7.25%
25.46
27.05
-5.88%
30.32
24.85
22.01%
29.77
26.50
12.34%
Depreciation
83.43
78.32
6.52%
69.56
78.44
-11.32%
73.90
77.40
-4.52%
72.41
76.26
-5.05%
PBT
367.34
211.66
73.55%
654.90
538.89
21.53%
648.04
402.33
61.07%
352.85
151.89
132.31%
Tax
62.86
143.98
-56.34%
50.62
78.93
-35.87%
33.15
54.61
-39.30%
65.04
20.44
218.20%
PAT
304.48
67.68
349.88%
604.28
459.96
31.38%
614.89
347.72
76.83%
287.81
131.45
118.95%
PATM
10.37%
2.33%
18.18%
15.13%
17.87%
-10.84%
9.70%
5.10%
EPS
24.56
5.94
313.47%
49.77
38.04
30.84%
51.90
-0.96
-
23.98
10.68
124.53%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
12,667.58
11,599.26
10,634.19
8,865.01
8,344.36
7,357.19
6,391.84
5,687.53
4,924.84
3,743.35
3,126.00
Net Sales Growth
9.21%
9.08%
19.96%
6.24%
13.42%
15.10%
12.38%
15.49%
31.56%
19.75%
 
Cost Of Goods Sold
4,937.58
4,381.43
3,565.78
3,124.81
2,959.14
2,586.30
1,986.45
1,807.71
1,630.87
1,453.41
1,168.05
Gross Profit
7,730.00
7,217.83
7,068.41
5,740.20
5,385.22
4,770.89
4,405.39
3,879.82
3,293.97
2,289.94
1,957.95
GP Margin
61.02%
62.23%
66.47%
64.75%
64.54%
64.85%
68.92%
68.22%
66.88%
61.17%
62.63%
Total Expenditure
10,422.09
9,989.81
8,581.27
6,922.62
6,870.97
6,242.42
5,382.92
4,688.58
4,071.59
3,321.52
2,716.05
Power & Fuel Cost
-
163.94
162.96
129.95
130.14
121.48
112.64
86.34
66.33
53.31
60.33
% Of Sales
-
1.41%
1.53%
1.47%
1.56%
1.65%
1.76%
1.52%
1.35%
1.42%
1.93%
Employee Cost
-
2,131.35
1,962.71
1,621.03
1,505.49
1,362.46
1,191.64
1,003.85
861.08
645.87
531.56
% Of Sales
-
18.37%
18.46%
18.29%
18.04%
18.52%
18.64%
17.65%
17.48%
17.25%
17.00%
Manufacturing Exp.
-
972.37
1,092.63
748.03
765.43
806.17
838.87
692.26
550.16
367.58
305.99
% Of Sales
-
8.38%
10.27%
8.44%
9.17%
10.96%
13.12%
12.17%
11.17%
9.82%
9.79%
General & Admin Exp.
-
819.84
641.25
506.77
525.62
512.52
469.90
379.78
334.28
238.92
184.73
% Of Sales
-
7.07%
6.03%
5.72%
6.30%
6.97%
7.35%
6.68%
6.79%
6.38%
5.91%
Selling & Distn. Exp.
-
1,339.88
1,070.10
700.98
854.48
726.21
675.43
596.44
503.69
434.56
367.31
% Of Sales
-
11.55%
10.06%
7.91%
10.24%
9.87%
10.57%
10.49%
10.23%
11.61%
11.75%
Miscellaneous Exp.
-
181.00
85.84
91.05
130.67
127.28
107.99
122.20
125.18
127.87
367.31
% Of Sales
-
1.56%
0.81%
1.03%
1.57%
1.73%
1.69%
2.15%
2.54%
3.42%
3.14%
EBITDA
2,245.49
1,609.45
2,052.92
1,942.39
1,473.39
1,114.77
1,008.92
998.95
853.25
421.83
409.95
EBITDA Margin
17.73%
13.88%
19.30%
21.91%
17.66%
15.15%
15.78%
17.56%
17.33%
11.27%
13.11%
Other Income
310.84
216.08
162.65
233.21
104.22
87.70
115.42
112.01
239.71
181.04
165.35
Interest
112.41
107.36
52.37
58.92
65.06
54.63
55.33
45.16
71.24
81.11
93.08
Depreciation
299.30
310.42
303.96
274.58
252.76
193.18
143.03
101.17
93.31
70.94
52.26
PBT
2,023.13
1,407.75
1,859.24
1,842.10
1,259.79
954.66
925.98
964.63
928.41
450.82
429.96
Tax
211.67
297.96
163.96
224.33
110.48
181.02
287.56
59.96
176.18
59.23
-5.36
Tax Rate
10.46%
22.84%
8.89%
12.18%
8.77%
18.96%
31.05%
6.22%
18.98%
13.14%
-1.25%
PAT
1,811.46
984.17
1,645.62
1,585.02
1,127.07
760.51
630.94
892.03
741.59
391.59
435.32
PAT before Minority Interest
1,795.77
1,006.81
1,680.32
1,617.77
1,149.31
773.64
638.42
904.67
752.23
391.59
435.32
Minority Interest
-15.69
-22.64
-34.70
-32.75
-22.24
-13.13
-7.48
-12.64
-10.64
0.00
0.00
PAT Margin
14.30%
8.48%
15.47%
17.88%
13.51%
10.34%
9.87%
15.68%
15.06%
10.46%
13.93%
PAT Growth
79.92%
-40.19%
3.82%
40.63%
48.20%
20.54%
-29.27%
20.29%
89.38%
-10.05%
 
EPS
151.46
82.29
137.59
132.53
94.24
63.59
52.75
74.58
62.01
32.74
36.40

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
9,045.29
8,637.90
7,376.73
6,160.67
5,439.34
4,863.77
4,467.64
3,691.96
2,999.05
2,584.97
Share Capital
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
11.96
Total Reserves
9,020.78
8,613.39
7,351.70
6,135.40
5,413.93
4,838.87
4,443.34
3,668.03
2,975.14
2,573.01
Non-Current Liabilities
-688.00
-892.74
-750.71
-540.58
-288.92
-358.61
-400.78
-306.15
200.60
323.92
Secured Loans
0.00
0.03
18.47
63.60
219.80
122.12
175.01
112.49
33.43
232.25
Unsecured Loans
0.00
9.35
9.46
10.31
11.50
8.61
6.55
10.97
0.00
0.00
Long Term Provisions
369.36
332.75
250.73
222.98
173.72
150.27
102.17
82.96
66.58
42.29
Current Liabilities
3,707.14
4,805.34
3,604.05
3,244.58
2,217.53
2,383.31
1,689.69
1,537.60
2,005.98
1,402.58
Trade Payables
1,165.03
1,173.38
1,069.41
954.05
962.25
960.71
741.37
580.48
465.93
305.73
Other Current Liabilities
838.80
771.42
643.11
555.47
428.08
520.04
339.25
366.01
327.06
201.28
Short Term Borrowings
1,307.12
2,570.62
1,635.96
1,503.51
671.27
761.27
472.37
464.17
1,128.57
845.22
Short Term Provisions
396.19
289.92
255.57
231.55
155.93
141.29
136.70
126.94
84.42
50.35
Total Liabilities
12,454.14
12,759.93
10,411.35
9,012.97
7,500.56
7,010.02
5,871.78
5,018.43
5,291.28
4,311.47
Net Block
2,682.83
2,901.73
2,792.98
2,908.01
2,530.44
2,283.59
1,797.04
1,449.54
1,374.34
1,170.01
Gross Block
4,050.23
4,185.64
3,768.89
3,606.95
3,026.08
2,603.78
1,977.20
1,538.64
1,744.89
1,170.01
Accumulated Depreciation
1,367.40
1,283.91
975.91
698.94
495.64
320.19
180.16
89.10
370.55
0.00
Non Current Assets
3,724.45
4,324.50
3,482.53
3,507.32
3,284.43
2,996.80
2,954.64
2,249.73
2,953.23
2,709.33
Capital Work in Progress
323.24
339.48
393.28
362.97
492.96
380.97
299.26
172.42
110.69
0.00
Non Current Investment
304.61
231.67
153.95
91.50
95.74
98.45
259.44
234.39
419.73
338.24
Long Term Loans & Adv.
139.07
154.44
93.77
98.16
118.64
141.37
193.07
142.35
542.17
418.40
Other Non Current Assets
274.70
697.18
48.55
46.68
46.65
92.42
405.83
251.03
506.30
782.68
Current Assets
8,606.43
8,433.70
6,928.82
5,505.65
4,216.13
4,013.22
2,917.14
2,768.70
2,338.05
1,602.14
Current Investments
317.21
139.31
178.83
169.89
227.88
345.82
293.56
274.18
61.05
249.77
Inventories
2,607.53
3,005.53
2,312.44
1,818.82
1,499.87
1,442.19
1,206.00
909.37
784.23
620.33
Sundry Debtors
2,132.19
1,884.60
1,607.21
1,649.36
1,248.41
1,080.50
713.64
567.51
527.08
366.93
Cash & Bank
2,616.89
2,578.58
1,990.45
1,092.21
661.60
576.78
399.26
780.90
790.76
206.29
Other Current Assets
932.61
239.80
335.19
293.13
578.37
567.93
304.68
236.74
174.93
158.82
Short Term Loans & Adv.
687.93
585.88
504.70
482.24
405.00
390.63
171.35
141.30
114.85
110.04
Net Current Assets
4,899.29
3,628.36
3,324.77
2,261.07
1,998.60
1,629.91
1,227.45
1,231.10
332.07
199.56
Total Assets
12,330.88
12,758.20
10,411.35
9,012.97
7,500.56
7,010.02
5,871.78
5,018.43
5,291.28
4,311.47

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
1,682.50
1,111.02
1,264.90
585.08
779.65
266.04
471.14
725.83
325.47
290.01
PBT
1,304.77
1,844.28
1,842.10
1,259.79
954.66
925.98
964.63
928.41
450.82
429.96
Adjustment
324.35
208.60
164.64
255.87
216.37
116.47
33.02
-14.42
-7.82
7.48
Changes in Working Capital
326.77
-544.96
-341.16
-647.20
-140.27
-573.24
-262.55
10.05
-11.89
-36.37
Cash after chg. in Working capital
1,955.89
1,507.92
1,665.58
868.46
1,030.76
469.21
735.10
924.04
431.11
401.07
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-273.39
-396.90
-400.68
-283.38
-251.11
-203.17
-263.96
-198.21
-105.64
-111.06
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
112.84
-1,435.13
-998.54
-741.35
-316.39
-357.23
-285.93
202.27
-236.97
350.44
Net Fixed Assets
-101.59
-254.26
-139.76
-310.63
-342.15
-531.27
-390.07
160.79
-111.90
-103.11
Net Investments
-476.94
-376.23
-196.34
-260.44
-151.10
-26.86
-359.97
-87.11
-129.77
-361.40
Others
691.37
-804.64
-662.44
-170.28
176.86
200.90
464.11
128.59
4.70
814.95
Cash from Financing Activity
-1,760.82
379.57
-271.75
79.15
-378.94
84.56
-137.88
-927.27
-51.78
-599.94
Net Cash Inflow / Outflow
34.52
55.46
-5.39
-77.12
84.32
-6.63
47.33
0.83
36.72
40.51
Opening Cash & Equivalents
232.18
174.22
175.94
249.05
166.71
166.63
127.03
123.75
100.82
57.31
Closing Cash & Equivalent
273.80
232.18
174.22
175.94
249.05
166.71
166.63
127.05
139.60
100.82

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
756.56
722.48
616.95
515.21
454.86
406.76
373.67
308.82
250.86
216.13
ROA
7.99%
14.50%
16.66%
13.92%
10.66%
9.91%
16.61%
14.59%
8.16%
10.14%
ROE
11.39%
20.99%
23.91%
19.82%
15.02%
13.69%
22.18%
22.47%
14.03%
18.28%
ROCE
13.09%
18.69%
22.56%
18.71%
16.49%
17.86%
21.31%
23.09%
13.27%
14.06%
Fixed Asset Turnover
4.36
3.84
3.56
3.74
3.80
3.75
3.33
3.07
2.65
2.89
Receivable days
40.86
41.72
45.33
42.66
39.69
38.15
39.95
39.57
42.27
38.62
Inventory Days
57.10
63.54
57.51
48.86
50.14
56.31
65.96
61.23
66.41
66.19
Payable days
97.40
114.79
118.18
52.05
60.17
61.04
52.36
49.96
45.83
42.61
Cash Conversion Cycle
0.57
-9.53
-15.34
39.47
29.66
33.42
53.55
50.84
62.85
62.19
Total Debt/Equity
0.14
0.30
0.23
0.26
0.17
0.21
0.15
0.18
0.44
0.44
Interest Cover
13.15
36.22
32.26
20.36
18.48
17.74
22.36
14.03
6.56
5.62

News Update:


  • Alkem Laboratories incorporates wholly owned subsidiary
    15th Jul 2024, 16:25 PM

    Alixer Nexgen Therapeutics has been incorporated to conduct research, studies, innovation work and develop novel medicines and treatments in key therapeutic areas

    Read More
  • USFDA issues EIR for Alkem Laboratories’ Baddi manufacturing facility
    25th Jun 2024, 15:25 PM

    The Inspection has been classified as Voluntary Action Indicated and has been closed accordingly

    Read More
  • Alkem Laboratories to invest Rs 30 crore in HaystackAnalytics
    6th Jun 2024, 18:21 PM

    The said transaction is expected to be completed on or before July 31, 2024 or such extended period as may be agreed upon

    Read More
  • Alkem Laboratories reports over 4-fold jump in Q4 consolidated net profit
    30th May 2024, 11:52 AM

    Total consolidated income of the company increased by 1.77% at Rs 3023.99 crore for Q4FY24

    Read More
  • Alkem Laboratories - Quarterly Results
    29th May 2024, 14:12 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.